THARIMMUNE INC (THAR)
US4327053090 - Common Stock
Why Is Verastem (VSTM) Stock Down 62% Today?
Verastem stock is down on Friday with heavy trading of VSTM shares alongside its latest pancreatic cancer clinical trial safety data.
Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today?
Sensei Biotherapeutics stock is falling on Friday as SNSE investors are unimpressed by its latest clinical trial data.
Why Is Tharimmune (THAR) Stock Moving Today?
Tharimmune stock is on the move Friday as investors prepare for a reverse split of THAR shares after markets close today.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
We're diving into the biggest pre-market stock movers that traders need to know about on Friday morning with all of the latest news!
THAR Stock Earnings: Tharimmune Reported Results for Q4 2023
Tharimmune just reported results for the fourth quarter of 2023.
Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
Dallas, Texas--(Newsfile Corp. - November 30, 2023) - Stonegate Healthcare Partners is pleased to...
Shein IPO Alert: 7 Things for Potential Shein Stock Investors to Know
Shein is in the news Tuesday as reports spread that the fast fashion company is preparing for an IPO that could take place in 2024.
Why Is SenesTech (SNES) Stock Down 36% Today?
SenesTech stock is falling on Tuesday after the company announced an offering for 3,846,154 shares of SNES at $1.30 per share.
Why Is Tharimmune (THAR) Stock Down 70% Today?
Tharimmune stock is falling on Tuesday after the clinical-stage biotechnology company announced a public offering for THAR shares.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers for Tuesday morning with all of the latest news you need to know today!
Tharimmune announces pricing of $10 million public offering (NASDAQ:THAR)
Tharimmune announces public offering of 10 million shares of common stock at $1.00 per share, with an option for further purchases.
Tharimmune stock rockets 46% on positive Phase 1 data for PBC drug (NASDAQ:THAR)
Shares of Tharimmune (THAR) rocketed 46% in mid-morning trading Monday after the company reported positive Phase 1 data for its drug candidate TH104 in the trea